merck deliv better expect figur
importantli provid solid outlook sale ebitda growth
limit headwind expect
upgrad buy see diverg current discount
peer compani underli perform organ sale
growth expect slightli ahead peer
result estim
sale expect organ sale thank strong
growth pharma life scienc segment pm
divis show signific organ decreas higher estim
ebitda expect posit contribut
divis also thank particularli strong transact exchang rate
solid guidanc despit
usual march merck guidanc qualit
solid organ turnov growth believ impli rang
strong organ ebitda adj growth believ impli hsd growth
ep target
incorpor estim outlook rais ep adj
target price base dcf move impli
price-to-earnings result updat earn well revis wacc
due lower risk free rate long term growth
due increas confid pharma pipelin azn
partnership exposur novel technolog gene edit note
merck current trade price-to-earnings discount peer blend
upgrad buy
improv rate buy consid
turnov relat life scienc tool consum use
 pharmaceut academi research test product
out-performance address market growth
support e-commerce site broad portfolio expos high
turnov relat product biolog drug
msd portfolio growth pipelin add sale
support mavenclad ramp-up multipl sclerosi peak
sale potenti new jv azn
sale link perform materi versum
mostli link consum organometal deposit film
special gase use semiconductor product end market
growth driven new lithographi technic
current price-to-earnings discount fundament valu
base dcf impli well sum part
calcul blend averag life scienc pharma
pm
stock datapric codemrk gymarket cap volum sxxp net ep ord yield xinterest
profit tax
compani data equita sim estim
merck kgaa base darmstadt germani oldest pharmaceut
chemic compani world root date back american
pharmaceut compani merck co establish subsidiari merck
becam independ origin merck darmstadt hold
right name merck countri except canada
known emd
compani today three busi segment
healthcar biolog drug treat cancer bavencio erbitux multipl sclerosi
rebif mavenclad infertil gonal-f growth disord saizen certain
cardiovascular metabol diseas concor glucophag euthyrox
lead world-wide supplier tool high-grad chemic
equip academ lab biotech biopharmaceut manufactur well
industri sector research solut provid academ custom
chemic tool need make scientif discoveri easier faster process
solut provid drug manufactur process develop expertis
technolog continu bioprocess appli solut offer test
kit servic ensur food safe eat water clean drink
perform materi compris specialti chemic busi merck
consist three busi unit semiconductor solut consum wafer
manufactur display solut liquid crystal surfac solut pigment
 market leadership life scienc
pharma pipelin could add risk adj
sale
risk china gpo healthcar
price deflat liquid crystal
 new pm portfolio growth bia
sale expect organ sale thank strong growth
pharma life scienc segment pm divis show
signific organ decreas higher estim division level
healthcar deliv organ sale growth thank solid core busi
acceler mavenclad uptak qoq
life scienc deliv organ sale growth bioprocess main
perform materi organ sale growth neg driven
neg underli trend liquid crystal given last year high base
semiconductor solut out-performance weak market
ebitda expect posit contribut divis
also thank particularli strong transact exchang rate effect
net debt close expect due cash outflow versum
acquisit underli cash gener strong
merck expect solid organ growth believ impli rang
group net sale compar previou year like driven
mainli healthcar life scienc busi sector perform
materi compani expect slight organ increas strong growth dynam
expect especi semiconductor materi busi
ebitda pre fiscal merck forecast strong organ growth believ
impli hsd growth mainli driven healthcar life scienc
busi sector perform materi also contribut slight organ growth
merck outlook includ also slight fx headwind assum rang
incorpor estim use ytd rate
merck guidanc includ sale headwind assum epidem
reach high point first quarter subsid cours second quarter
situat expect normal second half year
biopharma busi discov develop manufactur market innov
pharmaceut biolog prescript drug treat cancer ms infertil
growth disord certain cardiovascular metabol diseas
biopharma oper four franchis neurolog immunolog mavenclad rebif
gonal-f gener medicin
end march mavenclad cladribin tablet approv
unit state market greatest number peopl live ms
mavenclad approv treatment adult relapsing-remit ms
rrm activ secondari progress ms spm
cladribin tablet approv fda treatment rrm spm
provid two year proven efficaci maximum day oral
treatment two-year period approv mavenclad approv
countri includ european union australia canada
switzerland
believ mavenclad complementari oral treatment option ms product
portfolio includ histor blockbust rebif
rebif interferon disease-modifi drug use treat relaps form
ms rm remain well-establish therapi rebif regist
countri world-wide interferon proven delay
progress disabl reduc frequenc relaps reduc magnet
reson imag mri lesion activ area
septemb compani initi two global pivot phase trial
evobrutinib oral highli select bruton tyrosin kinas btk inhibitor adult
patient rm
erbitux cetuximab remain second best-sel drug term revenu
portfolio biopharma busi merck flagship product oncolog treat
patient sinc author product standard care
patient epiderm growth factor receptor egfr -express ra wildtyp
metastat colorect cancer mcrc well recurr and/or metastat
local advanc squamou cell carcinoma head neck scchn
compani continu invest cetuximab commit make avail
patient benefit
septemb erbitux obtain approv nation medic product
administr china mcrc
moreov merck togeth develop new treatment option
patient hard-to-treat cancer compani made key progress
area regulatori approv countri
antibodi avelumab brand name bavencio
may merck partner announc fda approv bavencio
combin axitinib first-lin treatment patient advanc renal
cell carcinoma rcc octob report european commiss ec
also approv bavencio combin axitinib first-lin treatment
adult patient advanc rcc bavencio initi grant two approv
fda treatment adult pediatr patient year older
metastat merkel cell carcinoma mmcc previous treat patient
local advanc metastat urotheli carcinoma uc indic
grant acceler approv base tumor respons rate durat
respons continu approv indic may conting upon
verif descript clinic benefit confirmatori trial prognosi
patient group poor avelumab may repres welcom new
bavencio approv base data comprehens clinic
develop program javelin current involv least clinic
program patient evalu across differ
tumor type merck continu explor potenti option
enter number strateg collabor evalu avelumab
combin rang complementari oncolog medicin
highlight pipelin cancer treatment includ present
new data investig oral inhibitor tepotinib advanc solid
import mileston two
combin studi tepotinib local advanc metastat non-smal cell lung
cancer nsclc epiderm growth factor receptor egfr mutat select
dysregul month merck announc fda grant
breakthrough therapi design btd tepotinib patient metastat
nsclc harbor exon skip alter progress follow
platinum-bas cancer therapi novemb merck report japanes
ministri labour welfar mhlw grant orphan drug design
odd tepotinib patient nsclc-harbor gene alter
septemb compani share
februari merck enter global strateg allianc glaxosmithklin
gsk jointli develop commerci investig bifunct fusion
protein immunotherapi bintrafusp alfa discov result
achiev allianc object eight trial on-going protocol
develop includ recent clinic trial initi octob
merck also global market leader fertil drug treatment
uniqu broad portfolio therapeut lab technolog fertil
franchis import growth driver biopharma busi
infertil repres increas challeng global due demograph chang
grow lifestyl adjust like delay childbear highli special
market focu lie qualiti standard outcom improv
compani best-sel product gonal-f compani introduc new
methodolog make product easi use pergoveri
first product combin recombin follicle-stimul hormon fsh
recombin
elimin need mix thu provid improv conveni
treatment option women sever defici fsh lh group
patient difficult treat
pergoveri launch countri continu
provid patient access innov therapeut occas
annual meet european societi human reproduct embryolog
launch medic innov program mip human
reproduct initi strive support earli stage innov key area
highlight compani continu commit open innov mip
support collabor co-develop bring togeth intern extern
expertis serv platform
interdisciplinari conceptu
methodolog debat provid new solut boost innov
ready-to-us
remain part portfolio gener medicin endocrinolog
gm medic includ drug concor euthyrox glucophag
gm largest busi franchis healthcar busi sector term
sale strong growth major therapeut area focu contribut
significantli overal profit biopharma merck
although longer patent-protect brand equiti product built
decad make cornerston treatment chronic cardiovascular
metabol endocrin diseas
glucophag contain activ ingredi metformin drug choic
first-lin treatment type diabet multipl health author
world-wide continu approv glucophag prediabet intens lifestyl
chang fail indic glucophag regist countri
overal consid high preval prediabet diabet see great
potenti glucophag
concor contain bisoprolol lead beta-block chronic cardiovascular
diseas hypertens coronari arteri diseas chronic heart failur
euthyrox activ ingredi levothyroxin world-wide market leader
market share volum treatment hypothyroid diseas
high preval still low diagnosi rate emerg market
saizen activ ingredi somatropin compani main endocrinolog
product indic treatment growth hormon defici children
adult
compani data equita sim estim
merck today thank success acquisit integr millipor
sigma aldrich lead global life scienc compani
busi oper three divis research solut process solut
appli solut busi unit suppli tool high-grad chemic
equip academ lab biotech biopharmaceut manufactur well
industri sector
research solut provid academ custom chemic tool
need make scientif discoveri easier faster
process solut provid drug manufactur process develop
expertis technolog continu bioprocess
appli solut offer test kit servic ensur food safe
eat water clean drink
global life scienc market larg expect grow per
year figur merck expect outperform given strong
e-commerce platform broad product portfolio presenc high growth market
mab gene/cel therapi
merck portfolio compris product rang lab water
system genome-edit tool antibodi cell line well end-to-end
bioprocess system support manufactur need emerg biotech
larg pharma compani
compani e-commerc platform sale www sigmaaldrich com
continu grow connect custom global product need
advanc research develop product effort expand e-
commerc reach life scienc becam first industri launch
offici flagship store alibaba china provid easi access high-
qualiti product solut custom countri
within process solut busi unit expect show strongest
growth merck top posit global across product valu chain
enabl compani retain larg client well captur new emerg biotech
februari life scienc made first sever announc regard
crispr intellectu properti portfolio genom edit
crispr simpl power programm genome-edit tool acronym
cluster regularli interspac short palindrom repeat crispr equival
molecular swiss armi knife compos two part first bodi
guid rna isol portion dna research wish
manipul second tool nucleas perform oper
stretch dna
crispr function core compet merck support research
genom edit care consider ethic legal standard
februari compani receiv first unit state patent proxy-
crispr technolog specif techniqu make crispr effici flexibl
specif open genom modif dna
merck portfolio includ patent crispr technolog grant world-wide
includ addit throughout canada europ israel south korea
unit kingdom japan singapor
juli compani simplifi path licens crispr technolog
commerci research product develop agreement
broad institut mit harvard massachusett unit state uniqu
offer life scienc collabor eas navig complex intellectu
properti landscap crispr patent encourag particip innov
area
anoth import innov introduc april launch
biocontinuum buffer deliveri platform
build block platform address intensifi bioprocess
continu manufactur integr solut tailor provid highest
level accuraci precis buffer prepar manag
configur platform suppli process buffer fraction resourc
facil space result streamlin buffer suit effici
launch mark key step merck strategi deliv contigu bioprocess
goe beyond connect individu unit oper includ orchestr
manag process step materi product test
analyt industry-lead streamlin optim approach
pilot studi suggest convers manufactur method may reduc
manufactur cost
busi consist three busi unit solut display
solut surfac solut
complet acquisit intermolecular septemb
versum materi octob compani reach improv
solut pro-forma recent acquisit largest
busi unit within perform materi consist two dedic unit
semiconductor materi deliveri system servic
materi unit suppli product everi major step
planar etch clean specialti cleaner conduct past
semiconductor packag round portfolio
deliveri system servic ds busi enabl safe respons
handl gase liquid chemic electron manufactur focus
develop deploy safe reliabl deliveri equip allow
materi handl highest qualiti safeti standard
area deposit materi compani continu look new
organosilan organometal materi well
formul process low resist variou dielectr characterist
faster better processor well higher data storag densiti
photoresist busi grow rapidli throughout year compani
develop new photoresist address need market exampl
nand memori sensor radio frequenc rf filter
space compani transient liquid phase sinter tlp conduct
past enabl highli effici product modern antenna applic
mid- back-end photolithographi resist materi use electron packag
applic continu drive miniatur heterogen integr
data volum grow annual semiconductor requir
data process storag merck benefit trend well
complex lithographi gener address market growth
measur million squar inch silicon wafer shipment
merck display solut busi unit compris liquid crystal organ
light-emit diod photoresist liquid crystal window busi
even though competit continu intensifi compani defend posit
global market technolog leader display materi busi
